Download the latest patient newsletter from July 2015 here


November 2015: CF clinical trials meeting scheduled for 13th November 2015

The aim of the meeting is to bring together professionals involved in CF clinical trials in the UK to share information on CF clinical trials that are currently recruiting, highlight new ones and discuss potential barriers to timely recruitment and how they can be overcome. Watch this space for further updates.................


March 2015: New podcast discussing the use of antibiotics to get rid of Pseudomonas aeruginosa in people with CF

Access the podcast here


January 2015: CF Trust and cf/Aware announce they will be running a clinical trials awareness week starting on 26th January 2015

 For more details see latest patient newsletter.


December 2014: Updated Cochrane review concludes there is still insufficient evidence to state which antibiotic strategy should be used for the eradication of early Pseudomonas aeruginosa infection in cystic fibrosis

Read more here


November 2014: Dr Kotwal, Consultant Paediatrician at Hull describes her experience of taking part in the trial

Read more here


September 2014: Patient with CF describes the challenges of managing her health at school

Read more here


July 2014: TORPEDO goes International!

The use of oral and intravenous antibiotics to treat new isolations of Pseudomonas aeruginosa is not only standard practice in the UK but also in many other countries in the world however, up to now the study has only been open in UK sites. Well that is about to change!

The study team have recently received confirmation that sites in Sweden and Italy will be opening to recruitment for TORPEDO making it the first investigator led study of it's kind to open to recruitment in Europe!

Watch this space for further developments..........


May 2014: New CF research from Northern Ireland

More and more young people with cystic fibrosis, who make the transition to adult care, are now free of chronic lung infection with Pseudomonas. Pseudomonas infection leads to a more rapid deterioration in lung function and a reduced life expectancy. Clinical trials have shown that, if the Pseudomonas infection is caught early, it can be eradicated. However most of these trials were done in children. Until now it was not known whether the same rates of eradication could be achieved in adults.

The paper by Kenny and colleagues in BMJ Open describes eradication treatment in 20 adults with CF and shows success rates comparable to trials in children with CF.

This emphasises the importance of adults and adult centres taking part in the TOR-PEDO study which aims to see which regimen (intravenous or oral) is the most effective in eradicating Pseudomonas. The opportunity to answer this question won't come round again! The TORPEDO team are very grateful to the adult centres and adult patients who have participated in TORPEDO already. Adult centres who are not already taking part are welcome to join and we encourage all adult patients to discuss the TORPEDO study with their CF doctor!

Read the paper by Kenny et al here


September 2012: Infection with Pseudomonas aeruginosa increases treatment costs substantially

A paper published in the Journal of Pharmacoeconomics has shown that the cost of treating CF patients rises substantially if patients are infected with Pseudo-monas aeruginosa (PsA). The research carried out in Germany in 2004 showed that the annual cost of treating a CF patient with PsA is greater by more than €29,000 compared to a PsA negative patient. The study concluded that reducing the infection rates of PsA would result in significant savings.

Read the paper by Heimeshoff et al here